APA (7th ed.) Citation

Liu, Y., Su, J., Wu, P., & Lv, W. (2025). Long-term efficacy of CDK4/6 inhibitors in early HR+, HER2- high-risk breast cancer: An updated systematic review and meta-analysis. Frontiers Media S.A.

Chicago Style (17th ed.) Citation

Liu, Ying, Jun Su, Ping Wu, and Wenjie Lv. Long-term Efficacy of CDK4/6 Inhibitors in Early HR+, HER2- High-risk Breast Cancer: An Updated Systematic Review and Meta-analysis. Frontiers Media S.A, 2025.

MLA (9th ed.) Citation

Liu, Ying, et al. Long-term Efficacy of CDK4/6 Inhibitors in Early HR+, HER2- High-risk Breast Cancer: An Updated Systematic Review and Meta-analysis. Frontiers Media S.A, 2025.